Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• S&P 500 may pull back before midterms, but Citi says buy the dip